https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Patient and health care professional acceptability of pharmacogenetic screening for DPYD and UGT1A1: a cross sectional survey. https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54477 Tue 27 Feb 2024 14:56:37 AEDT ]]> Pharmacogenetics testing (DPYD and UGT1A1) for fluoropyrimidine and irinotecan in routine clinical care: Perspectives of medical oncologists and oncology pharmacists https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54138 Tue 06 Feb 2024 11:56:59 AEDT ]]> A systematic review and meta-analysis of toxicity and treatment outcomes with pharmacogenetic-guided dosing compared to standard of care BSA-based fluoropyrimidine dosing https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48437 Thu 16 Mar 2023 14:25:14 AEDT ]]>